This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Screening of potential biomarkers for polycystic ovary syndrome and identification of expression and immune characteristics
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOvarian function and disorders · Lipid metabolism and disorders · Ovarian cancer diagnosis and treatment
Following the publication of this article [1], the corresponding author contacted PLOS requesting the retraction of the article, stating that the underlying code required for the bioinformatics analyses reported in this study, including the RFE algorithm, LASSO regression, and ssGSEA scripts, are no longer available. The corresponding author states that in the absence of the code, the validity of key methodological steps, such as the biomarker screening process (e.g., JDP2 and HMOX1) and the accuracy of the immune infiltration analysis cannot be verified.
In light of these concerns, which question the reliability and validity of the published results, the PLOS One Editors agreed to retract the article.
All authors agree with the retraction and apologize for the issues with the published article.
The reference list from the paper itself. Each links out to its DOI / PubMed record.